Bazedoxifene, a medication that alters the activity of the sex hormone estrogen, was safe and well-tolerated but did not promote myelin repair in women with multiple sclerosis (MS) in a Phase 2 clinical trial. The findings come from the ReWRAP study (NCT04002934) and were presented last week at the Americas Committee for Treatment and Research […]
The post ACTRIMS 2026: Bazedoxifene fails to boost myelin repair in women with MS appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com